Regulation of inflammatory responses by natural anticoagulants

Immunological Reviews

Volumn 184, Issue , 2001, Pages 258-274

  Okajima, Kenji ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 3 ACETOXYMETHYL 2 (2 CARBOXY 1 PYRROLIDINYLCARBONYL) 7ALPHA METHOXY 8 OXO 5 THIA 1 AZABICYCLO[4.2.0]OCT 2 ENE 5,5 DIOXIDE; 3,5 DIMETHYL 2 (3 PYRIDYL) 4 THIAZOLIDINONE; ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; CYTOKINE; FIBRIN DEGRADATION PRODUCT; GABEXATE MESILATE; GLYCOSAMINOGLYCAN; HEPARIN DERIVATIVE; ILOPROST; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEUKOCYTE ELASTASE; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; NAFAMSTAT MESILATE; OXYGEN RADICAL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTACYCLIN; PROSTAGLANDIN; RECOMBINANT THROMBOMODULIN; SIVELESTAT; THROMBIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ACUTE KIDNEY FAILURE; BLOOD CLOTTING; BLOOD VESSEL INJURY; DISSEMINATED INTRAVASCULAR CLOTTING; GASTROINTESTINAL DISEASE; HUMAN; INFLAMMATION; LIVER FAILURE; LIVER INJURY; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; RESPIRATORY FAILURE; REVIEW; SEPTIC SHOCK; SPINAL CORD INJURY;

ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; HUMANS; INFLAMMATION; LIPOPROTEINS; PROTEIN C; RATS; THROMBOMODULIN;

EID: 0035707639     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065x.2001.1840123.x     Document Type: Review

References (153)

1. The role of leukocytes in disseminated intravascular coagulation associated with sepsis
2. Anticoagulant pretreatment attenuates production of cytokine-induced neutrophil chemoattractant following ischemia-reperfusion of rat liver
3. Cytokines and endothelial cell biology
4. Modulation of endothelial cell hemostatic properties by tumor necrosis factor
5. Activation of human polymorphonuclear neutrophil functions by interferon-γ and tumor necrosis factors
6. Proteolysis by neutrophils
7. An oxygen-dependent mechanism of neutrophil-mediated cytotoxicity
8. Human neutrophil elastase increases permeability of cultured pulmonary endothelial cell monolayer
9. The anti-inflammatory properties of antithrombin III. New therapeutic implications
10. Regulation of coagulation and inflammation by the thrombomodulin/protein C system in sepsis
11. Neuroinflammation as an important pathogenic mechanism in spinal cord injury
12. Pathogenesis of disseminated intravascular coagulation in sepsis
13. Role of leukocytes in the activation of intravascular coagulation in patients with septicemia
14. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture
15. Human recombinant interleukin-1β- and tumor necrosis factor-α-mediated suppression of heparin-like compounds on cultured porcine aortic endothelial cells
16. Cytokine activation of vascular endothelium
17. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans
18. The cell biology of macrophage activation
19. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees
20. Protective effect of anti-interleukin (IL)-6 antibody against endotoxin, associated with paradoxically increased IL-6 levels
21. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans
22. Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and baboons
23. Antithrombin III deficiency in surgical intensive care patients
24. Endotoxin-induced pulmonary vascular injury is mainly mediated by activated neutrophils in rats
25. Antithrombin III (AT III) prevents LPS-induced pulmonary vascular injury: Novel biological activity of AT III
26. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production
27. Pathogenetic mechanisms of septic shock
28. Immunologic therapy for ARDS, septic shock and multiple organ failure
29. Neutrophil-mediated damage to human vascular endothelium. Role of cytokine activation
30. The role of endothelial cells in inflammation
31. Tumor necrosis factor induces adult respiratory distress syndrome in rats
32. Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes
33. Platelet-activating factor antagonists as therapeutic strategy in sepsis
34. Role of PAF and cytokines in microvascular tissue injury
35. Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats
36. A novel platelet-activating factor antagonist, SM-12502, attenuates endotoxin-induced disseminated intravascular coagulation and acute pulmonary vascular injury by inhibiting TNF production in rats
37. Human plasma kallikrein release neutrophil elastase during blood coagulation
38. Purified plasma factor XIIa aggregates human neutrophils and causes degranulation
39. Effects of plasma kallikrein specific inhibitor and active-site blocked factor VIIa on the pulmonary vascular injury induced by endotoxin in rats
40. Therapeutic regulation of the complement system in acute injury state
41. Role of complement in endotoxin/platelet-activating factor-induced lung injury
42. Effect of nafamostat mesilate on the activity of extrinsic pathway of coagulation
43. Inhibition of tissue-F. VIIa complex by nafamostat mesilate; A reply to the rebuttal
44. Nafamostat mesilate
45. Effect of nafamostat mesilate on pulmonary vascular injury induced by lipopolysaccharide in rats
46. The pathogenesis of sepsis
47. Nitric oxide as a secretory product of mammalian cells
48. Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock
49. The nitric oxide and cGMP signal transduction system: Regulation and mechanism of action
50. The role of the L-arginine: Nitric oxide pathway in circulatory shock
51. 2+-independent nitric oxide synthase in the myocardium
52. Interferon-γ and tumor necrosis factor induce the L-arginine-dependent cytotoxic effector mechanism in murine macrophages
53. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits
54. Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide
55. Influence of oxygen-derived free radical scavengers on ischemic livers
56. Prevention and treatment of ischemia of the liver
57. Macrophage-mediated modulation of hepatic function in multi-system failure
58. The production of tumor necrosis factor alpha and the development of a pulmonary capillary injury following hepatic ischemia/reperfusion
59. Interleukin 1 receptor blockade reduces tumor necrosis factor production, tissue injury, and mortality after hepatic ischemia-reperfusion in the rat
60. Adenosine and selective A2A receptor agonists reduce ischemia/reperfusion injury of rat liver mailnly by inhhiting leukocyte activation
61. Gabexate mesilate, a synthetic protease inhibitor, reduces ischemia/reperfusion injury of rat liver by inhibiting leukocyte activation
62. Role of granulocyte elastase in ischemia/reperfusion injury of rat liver
63. Human neutrophil elastase increases permeability of cultured pulmonary endothelial cell monolayers
64. Tumor necrosis factor α-induced E-selectin expression is activated by the nuclear factor-κB and c-JUN N-terminal kinase/p38 mitogen-activated protein kinase pathways
65. A dual-binding antibody to E- and L-selectin attenuates sepsis-induced lung injury
66. Acute renal failure
67. Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury
68. α-melanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats
69. Early postischaemic renal fibrin deposition and reduction of glomerular filtration rate in the rat: Effect of the defibrinating agent Arwin
70. Effect of anticoagulation upon nephron obstruction in experimental acute ischaemic renal failure. A morphological study
71. An in vitro model of ischemia/reperfusion-induced microvascular injury
72. Adhesion molecules in renal disease
73. Role of neutrophil elastase in stress-induced gastric mucosal injury in rats
74. Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation
75. Involvement of endogenous interleukin-10 and tumor necrosis factor-alpha in renal ischemia-reperfusion injury
76. Cytoprotection by prostaglandins
77. Cytoprotection of canine gastric mucosa by prostacyclin: Possible mediation by increased mucosal blood flow
78. The microcirculation and inflammation: Modulation of leukocyte-endothelial cell adhesion
79. 2) in chloralose anesthetized dogs
80. Effects of prostacyclin (PGx) on cyclic AMP concentration in human platelets
81. Novel role of prostacyclin in stress-induced gastric mucosal lesion formation in rats
82. The effect of nocloprost, nileprost, iloprost and (15 S)-15-methyl-PGE2 on gastric mucosal damage induced by stress, indomethacin and ethanol
83. Activation of genes for superoxide dismutase, interleukin-1b, tumor necrosis factor-α and intercellular adhesion molecule-1 during healing of ischemia-reperfusion-induced gastric injury
84. Elastase and cathepsin G; the serine protease of human neutrophil leukocytes and spleen
85. Role of hydrogen peroxide in neutrophil-mediated destruction of cultured endothelial cells
86. Human leukocyte cathepsin G and elastase specifically suppress thrombin-induced prostacyclin production in human endothelial cells
87. Effects of neutrophil elastase and other proteases on porcine aortic endothelial prostaglandin I2 production, adenine nucleotide release, and responses to vasoactive agents
88. Effect of neutropenia on gastric mucosal integrity and mucosal nitric oxide synthesis in the rat
89. Effect of FK506, an immunosuppressive agent, on genesis of water-immersion stress-induced gastric lesions in rats
90. Rebamipide attenuates indomethacin-induced gastric mucosal lesion formation by inhibiting activation of leukocytes in rats
91. Rebamipide prevents indometahcin-induced gastric mucosal injury by inhibiting neutrophil activation
92. Plaunotol prevents indomethacin-induced gastric mucosal injury in rats by inhibiting neutrophil activation
93. Inhibition of neutrophil activation by ranitidine contributes to prevent stress-induced gastric mucosal injury in rats
94. 2 in rats
95. Activated neutrophils impair gastric cytoprotection: Role of neutrophil elastase
96. Lafutidine, a novel H2 receptor antagonist, reduces the stress-induced gastric mucosal injury by inhinbiting neutrophil activation through activation of capsaicin-sensitive sensory nerve in rats
97. Role of granulocyte elastase in indomethacin-induced gastric mucosal lesion formation in rats
98. Gastric prostacyclin (PGI2) prevents stress-induced gastric mucosal injury in rats primarily by inhibiting leukocyte activation
99. Spinal cord injury in the rat
100. Role of leukocytes in spinal cord injury in rats
101. Production of tumor necrosis factor in spinal cord following traumatic injury in rats
102. Sequential expression of c-fos protooncogene, TNFα, and dynorphin genes in spinal cord following experimental traumatic injury
103. Protective effect of vitamin E on spinal cord injury by compression and concurrent lipd peroxidation
104. Spinal cord restitution following compression injuries in rats
105. Expression of pro-inflammatory cytokine and chemokine mRNA upon experimental spinal cord injury in mouse: An in situ hybridization study
106. Nuclear factor κ B: An oxidative stress-responsive transcripition of eukaryotic cells
107. Leukocyte-endothelial adhesion molecules
108. Stimulation of neutrophils by tumor necrosis factor
109. Role of endothelial-leukocyte adhesion mokecule 1 (ELAM- 1) in neutrophil-mediated lung injury in rats
110. Gabexate mesilate, a synthetic protease inhibitor, prevents compression-induced spinal cord injury by inhibiting activation of leukocytes in rats
111. Role of neutrophils in spinal cord injury in the rat
112. Consequences of leukocyte-vessel wall interactions in inflammatory and immune reactions
113. Reperfusion-induced leukocyte infiltration: Role of neutrophil elastase
114. Role of neutrophil elastase in compression-induced spinal cord injury in rats
115. Reduction of spinal cord injury by administration of iloprost, a stable prostacyclin analog
116. Biochemistry of heparin antithrombin interactions, and the physiological role of this natural anticoagulant mechanism
117. Antithrombin mutation database: 2nd (1997) update
118. Antithrombin III "Nagasaki" (Ser116-Pro): A heterozygous variant with defective heparin binding associated with thrombosis
119. Prostaglandins prevent inducible nitric oxide synthase protein expression by inhibiting nuclear factor-κB activation in J774 macrophages
120. Effects of prostaglandins and cyclic AMP on cytokine production in rat leukocytes
121. Elevated cyclic AMP inhibits NF-κB-mediated transcription in human monocytic cells and endothelial cells
122. Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats
123. Inhibition by antithrombin of nitric oxide synthase induction in rats
124. Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin
125. COX-1 and COX-2 tissue expression: Implications and predictions
126. NS-398, a novel nonsteroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions
127. Selective inhibition of NS-398 on prostanoid production in inflamed tissue in rat carrageenan-airpouch inflammation
128. Comparative study between steroidal and nonsteroidal antiinflammatory drugs on the mode of their actions on vascular permeability in rat carrageenan-air-pouch inflammation
129. Antithrombin prevents stress-induced gastric mucosal injury by increasing gastric prostacyclin level in rats
130. Antithrombin does not directly promote the endothelial production of prostacyclin in cultured endothelial cells
131. Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C
132. The protein C anticoagulant pathway
133. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity
134. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon
135. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage
136. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibting activated leukocytes in rats
137. Activated protein C reduces the severity of compression-induced spinal cord injury in rats by inhibiting leukocyte activation
138. Spinal cord complications of thorachoabdominal aneurysm surgery
139. Activated protein C reduces the ischemia-induced spinal cord injury in rats by inhibiting neutrophil activation
140. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor κB (NF-κB) and tumour necrosis factor α (TNF-α) production in the THP-1 monocytic cell line
141. Activated protein C inhibits LPS-induced production of TNF-α by monocytes through inhibition of activation of NFκB and MAPK pathways
142. Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C
143. Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats
144. Recombinant thrombomodulin prevents endotoxin-induced lung injury by inhibiting activation of leukocytes in rats
145. Recombinant thrombomodulin prevents the endotoxin-induced increase in pulmonary vascular permeability through protein C activation
146. Effect of urinary thrombomodulin on endotox-ininduced intravascular coagulation and pulmonary vascular injury in rats
147. Neuroprotection by recombinant thrombomodulin
148. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor
149. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: Evidence supporting a physiologic role for EPI as a natural anticoagulant
150. Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction
151. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock
152. Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation
153. Recombinant tissue factor pathway inhibitor prevents lipopolysacckaride-induced systemic hypotension in rats by inhibiting excessive production of nitric oxide